Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: Follow-up results

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2177-2187

  Kantarjian, Hagop M ^a   Talpaz, Moshe ^a   O'Brien, Susan ^a   Smith, Terry L ^a   Giles, Francis J ^a   Faderl, Stefan ^a   Thomas, Deborah A ^a   Garcia Manero, Guillermo ^a   Issa, Jean Pierre J ^a   Andreeff, Michael ^a   Kornblau, Steven M ^a   Koller, Charles ^a   Beran, Milosav ^a   Keating, Michael ^a   Rios, Mary Beth ^a   Shan, Jenny ^a   Resta, Debra ^a   Capdeville, Renaud ^a   Hayes, Kimberly ^a   Albitar, Maher ^a   Freireich, Emil J ^a   Cortes, Jorge E ^a   more..

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; AGE; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BASOPHILIA; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CLONE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG EFFICACY; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT FAILURE; CHROMOSOME ANALYSIS; CHRONIC DISEASE; DRUG ANTAGONISM; MIDDLE AGED; MORTALITY; MYELOID LEUKEMIA; PATHOLOGY; TREATMENT OUTCOME;

CHRONIC DISEASE; CYTOGENETIC ANALYSIS; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMAN; INTERFERON-ALPHA; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGE; PIPERAZINES; PROGNOSIS; PROTEIN-TYROSINE KINASE; PYRIMIDINES; SUPPORT, NON-U.S. GOV'T; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; HUMANS; MIDDLE AGED; PROTEIN-TYROSINE KINASES;

EID: 0035992329     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Induction of chronic myelogenous leukemia: Current status and investigational options
2. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr/abl
3. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
4. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia
5. Chronic myelogenous leukemia with p185(BCR/ABL) expression: Characteristics and clinical significance
6. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
7. Neutrophilic-chronic myeloid leukemia
8. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
9. Bone marrow transplantation for chronic myeloid leukemia: Long-term results
10. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation
11. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase
12. Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase
13. Chronic myelogenous leukemia: A review
14. Interferon-α produces sustained cytogenetic responses in chronic myelogenous leukemia
15. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy
16. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon α and low-dose cytarabine
17. Treatment of advanced Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine
18. Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon α-2a compared with conventional chemotherapy for the treatment of chronic myeloid leukemia
19. UK medical research council randomized multi-center trial of interferon-αn1 for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response
20. Interferon α versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials
21. Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia
22. Interferon α-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
23. Cytarabine increases karyotypic response and survival in α-IFN treated chronic myelogenous leukemia patients: Results of a national prospective randomized trial of the Italian Cooperative Study Group on CML
24. Monitoring treatment and survival in chronic myeloid leukemia
25. Chronic myelogenous leukemia: Biology and therapy
26. Treatment of chronic myelogenous leukemia: Current status and investigational options
27. Therapeutic choices in younger patients with chronic myelogenous leukemia
28. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase
29. Results of decitabine therapy in accelerated and blastic phase of chronic myelogenous leukemia
30. Results of therapy with interferon α and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase
31. Chronic myelogenous leukemia in nonlymphoid blastic phase. Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
32. Intensive treatment in order to minimize the Ph-positive clone in CML
33. GM-CSF and interferon (IFN) rapidly induce cytogenetic remissions in chronic myeloid leukemia (CML)
34. GM-CSF can improve the cytogenetic response obtained with interferon-α therapy in patients with chronic myelogenous leukemia
35. Intensive chemotherapy induction followed by interferon-α maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
36. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
37. r 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
38. Activity of specific inhibitor of the BCR-ABL tyrosine in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome
39. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia
40. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
41. Gleevec (formerly STI571): An active drug in patients with Ph+ chronic myeloid leukemia in accelerated phase-updated results of a Phase II study
42. Gleevec/Glivec (imatinib mesylate, ST1571) in patients with chronic myeloid leukemia (CML) in myeloid blast crisis: Updated results of a Phase II study
43. Nonparametric estimation from incomplete observations
44. Evaluation of survival data and two new rank order statistics arising in its consideration
45. Regression models and life tables
46. Analysis of survival by tumor response
47. Determinants of prognosis in late chronic-phase chronic myelogenous leukemia
48. Long-term follow-up results of α-interferon-based regimens in patients with late chronic-phase chronic myelogenous leukemia
49. Imatinib mesylate (ST1571) therapy of Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in early chronic phase (Ph + CML early CP)
50. Early treatment decisions with interferon-α therapy in early chronic-phase chronic myelogenous leukemia